Significantly increased fractions of transformed to total α2-macroglobulin concentrations in plasma from patients with multiple sclerosis

IF 4.2 2区生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Biochimica et biophysica acta. Molecular basis of disease Pub Date : 2004-11-05 DOI:10.1016/j.bbadis.2004.06.010

Poul Erik H. Jensen, Signe Humle Jørgensen, Pameli Datta, Per Soelberg Sørensen

{"title":"Significantly increased fractions of transformed to total α2-macroglobulin concentrations in plasma from patients with multiple sclerosis","authors":"Poul Erik H. Jensen, Signe Humle Jørgensen, Pameli Datta, Per Soelberg Sørensen","doi":"10.1016/j.bbadis.2004.06.010","DOIUrl":null,"url":null,"abstract":"<div><div>We examined the proteinase inhibitor α<sub>2</sub>-macroglobulin (α<sub>2</sub>M) in plasma from patients with multiple sclerosis (MS); a neurological disease of the central nervous system. The plasma concentrations of native and transformed α<sub>2</sub>M were measured in 90 patients with clinically definite MS, 73 with relapsing–remitting and 17 with secondary progressive MS, and 132 healthy individuals. Significantly lower concentrations of native α<sub>2</sub>M and significantly higher concentrations of transformed α<sub>2</sub>M were found in MS patients. A significant correlation between the concentrations of native and transformed α<sub>2</sub>M was found. The fraction of transformed to total α<sub>2</sub>M in the MS patients was 36% higher than in the healthy individuals. The results suggest an important involvement of α<sub>2</sub>M in regulation of increased proteolytic activity occurring in MS disease.</div></div>","PeriodicalId":8821,"journal":{"name":"Biochimica et biophysica acta. Molecular basis of disease","volume":"1690 3","pages":"Pages 203-207"},"PeriodicalIF":4.2000,"publicationDate":"2004-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimica et biophysica acta. Molecular basis of disease","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0925443904001036","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

We examined the proteinase inhibitor α₂-macroglobulin (α₂M) in plasma from patients with multiple sclerosis (MS); a neurological disease of the central nervous system. The plasma concentrations of native and transformed α₂M were measured in 90 patients with clinically definite MS, 73 with relapsing–remitting and 17 with secondary progressive MS, and 132 healthy individuals. Significantly lower concentrations of native α₂M and significantly higher concentrations of transformed α₂M were found in MS patients. A significant correlation between the concentrations of native and transformed α₂M was found. The fraction of transformed to total α₂M in the MS patients was 36% higher than in the healthy individuals. The results suggest an important involvement of α₂M in regulation of increased proteolytic activity occurring in MS disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多发性硬化症患者血浆转化α2-巨球蛋白到总α2-巨球蛋白的浓度显著升高

我们检测了多发性硬化症（MS）患者血浆中蛋白酶抑制剂α2-巨球蛋白（α2M）的含量；中枢神经系统的一种神经系统疾病。测定90例临床明确多发性硬化症患者、73例复发缓解型多发性硬化症患者、17例继发性进展型多发性硬化症患者和132名健康个体的血浆天然α2M和转化α2M浓度。MS患者体内天然α2M浓度明显降低，转化α2M浓度明显升高。原生α2M浓度与转化α2M浓度呈显著相关。MS患者转化α2M占总α2M的比例比健康人高36%。结果表明α2M在MS疾病中蛋白水解活性增加的调控中起重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biochimica et biophysica acta. Molecular basis of disease 生物-生化与分子生物学

CiteScore

12.30

自引率

0.00%

发文量

218

审稿时长

32 days

期刊介绍： BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease. This journal covers aspects of aging, cancer, metabolic-, neurological-, and immunological-based disease. Manuscripts focused on using animal models to elucidate biochemical and mechanistic insight in each of these conditions, are particularly encouraged. Manuscripts should emphasize the underlying mechanisms of disease pathways and provide novel contributions to the understanding and/or treatment of these disorders. Highly descriptive and method development submissions may be declined without full review. The submission of uninvited reviews to BBA - Molecular Basis of Disease is strongly discouraged, and any such uninvited review should be accompanied by a coverletter outlining the compelling reasons why the review should be considered.